These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 12952110)

  • 1. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P; Casale T; Townley R; Tripathy I; Hedgecock S; Fowler-Taylor A; Shen H; Fox H
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):160-7. PubMed ID: 12952110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
    Okubo K; Ogino S; Nagakura T; Ishikawa T
    Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab is effective in the long-term control of severe allergic asthma.
    Lanier BQ; Corren J; Lumry W; Liu J; Fowler-Taylor A; Gupta N
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J; Diaz-Sanchez D; Saxon A; Deniz Y; Reimann J; Sinclair D; Davancaze T; Adelman D
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):243-8. PubMed ID: 15478383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
    Berger W; Gupta N; McAlary M; Fowler-Taylor A
    Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
    Cruz AA; Lima F; Sarinho E; Ayre G; Martin C; Fox H; Cooper PJ
    Clin Exp Allergy; 2007 Feb; 37(2):197-207. PubMed ID: 17250692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluticasone furoate nasal spray is effective and well tolerated for perennial allergic rhinitis in adolescents and adults.
    Given JT; Cheema AS; Dreykluft T; Stillerman A; Silvey M; Wu W; Snowise NG; Philpot E
    Am J Rhinol Allergy; 2010; 24(6):444-50. PubMed ID: 21144223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis.
    Dockhorn R; Aaronson D; Bronsky E; Chervinsky P; Cohen R; Ehtessabian R; Finn A; Grossman J; Howland W; Kaiser H; Pearlman D; Sublett J; Ratner P; Settipane G; Sim T; Storms W; Webb R; Drda K; Wood C
    Ann Allergy Asthma Immunol; 1999 Apr; 82(4):349-59. PubMed ID: 10227333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
    Adelroth E; Rak S; Haahtela T; Aasand G; Rosenhall L; Zetterstrom O; Byrne A; Champain K; Thirlwell J; Cioppa GD; Sandström T
    J Allergy Clin Immunol; 2000 Aug; 106(2):253-9. PubMed ID: 10932067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis.
    Nathan RA; Berger W; Yang W; Cheema A; Silvey M; Wu W; Philpot E
    Ann Allergy Asthma Immunol; 2008 May; 100(5):497-505. PubMed ID: 18517084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J; Figliomeni M; Kianifard F; Meng X
    J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.